Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $764M | $796M | $860M | $955M | $862M | $1.01B | $1.05B | $1.24B | $1.31B | $1.37B |
| Revenue growth | — | 4.3% | 7.9% | 11.1% | -9.7% | 17.2% | 3.4% | 19.1% | 5.0% | 5.2% |
| Gross profit | $408M | $431M | $469M | $525M | $460M | $568M | $571M | $676M | $733M | $750M |
| Gross margin | 53.5% | 54.1% | 54.6% | 54.9% | 53.4% | 56.2% | 54.6% | 54.3% | 56.1% | 54.6% |
| Operating income | $37.7M | $46.9M | $71.3M | $79.1M | $46.0M | $110M | $70.1M | $121M | $200M | $103M |
| Operating margin | 4.9% | 5.9% | 8.3% | 8.3% | 5.3% | 10.9% | 6.7% | 9.7% | 15.3% | 7.5% |
| Net income | $14.7M | $55.5M | $40.9M | $28.6M | $9.52M | $62.5M | -$80.6M | $64.5M | $132M | $47.1M |
| Net margin | 1.9% | 7.0% | 4.8% | 3.0% | 1.1% | 6.2% | -7.7% | 5.2% | 10.1% | 3.4% |
| EPS (diluted) | $0.52 | $1.97 | $1.41 | $0.97 | $0.32 | $1.94 | -$2.68 | $2.04 | $4.25 | $1.51 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $39.9M | $65.6M | $74.7M | $95.1M | $64.5M | $112M | $33.4M | $125M | $167M | $171M |
| Capital expenditures | $14.8M | $12.8M | $16.5M | $20.1M | $13.0M | $14.9M | $21.8M | $19.0M | $13.1M | $19.8M |
| Free cash flow | $25.1M | $52.7M | $58.2M | $75.1M | $51.5M | $96.9M | $11.6M | $106M | $154M | $151M |
| Share buybacks | $0.00 | — | — | — | — | — | — | — | — | — |
| Dividends paid | $22.2M | $22.3M | $22.4M | $22.6M | $22.8M | $23.3M | $24.0M | $24.5M | $24.7M | $24.7M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $27.4M | $32.6M | $17.5M | $25.9M | $27.4M | $20.8M | $28.9M | $24.3M | $24.5M | $40.8M |
| Total assets | $1.33B | $1.36B | $1.37B | $1.78B | $1.75B | $1.77B | $2.30B | $2.30B | $2.31B | $2.33B |
| Total liabilities | $748M | $727M | $707M | $1.06B | $1.04B | $981M | $1.55B | $1.47B | $1.34B | $1.29B |
| Long-term debt | $488M | $472M | $439M | — | — | — | — | — | — | — |
| Shareholders' equity | $581M | $631M | $662M | $710M | $709M | $785M | $746M | $834M | $963M | $1.03B |
| Retained earnings | $407M | $440M | $465M | $471M | $457M | $497M | $413M | $453M | $560M | $589M |
| Shares (wtd avg diluted) | 28.0M | 28.2M | 28.9M | 29.5M | 29.5M | 32.2M | 30.0M | 31.5M | 31.1M | 31.1M |
Every figure is extracted from CONMED Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.